Aligos Therapeutics arrived at the second quarter of 2026 in the middle of its most consequential bet: turning a clinical-stage pipeline built for chronic hepatitis B and liver disease into a business that funds its own path to data, with a founding-CEO-led team now leaning on a single Greater China partner for a critical infusion of non-dilutive cash. The quarter's headline looked like a turn - a reported net loss of roughly $1.5 million against $15.9 million a year earlier, and a dipped-to-positive pre-tax result on paper. That is a mirage built on two one-time items, not an operating inflection.
What actually happened matters more than the income statement's surface. In May Aligos signed the Amoytop license, granting Xiamen Amoytop Biotech exclusive rights to develop and commercialize pevifoscorvir sodium - its lead capsid-assembly modulator for chronic HBV - across Greater China for a $25 million upfront (net of tax, received in July) and up to $420 million in milestones plus tiered high single-digit royalties. That $25 million transaction drove the entire $27.8 million of licensing revenue that nearly erased the quarterly loss. Strip it out and the underlying operating result was a roughly $29.7 million loss, wider than the year-earlier $18.6 million, because research and development spend was roughly 70% higher with the enrollment build in its Phase 2 B-SUPREME trial. The warrant fair-value mark added another $3.0 million of non-cash income.
The investment tension is therefore not whether the loss narrowed - it did, mechanically - but whether the company's cash can reach the value-defining catalyst. Cash and investments stood at $30.4 million at June 30, and management guides that the cash plus the $25 million received in July funds planned operations only into the fourth quarter of 2026. That is under a year from this report, and the B-SUPREME topline readout that carries most of the pipeline's value is not due until late in the third quarter of 2027. The license bought a quarter or two; the gap between the runway and the readout is the crux. What decides the thesis: whether Aligos raises or partners before the cash runs out, whether the B-SUPREME data land on schedule and deliver superiority, and whether the warrant-driven earnings volatility ever gives way to cash that actually funds the pipeline.